- Title
- 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial
- Creator
- Farrell, Michael; Shahbazi, Jeyran; Nielsen, Suzanne; Dunlop, Adrian; Dore, Gregory J.; McDonough, Michael; Montebello, Mark; Weiss, Rob; Rodgers, Craig; Cook, Jon; Degenhardt, Louisa; Chambers, Mark; Byrne, Marianne; Gholami, Jaleh; Zahra, Emma; Grebely, Jason; Lintzeris, Nicholas; Larance, Briony; Ali, Robert
- Relation
- International Journal of Drug Policy Vol. 127, no. 104390
- Publisher Link
- http://dx.doi.org/10.1016/j.drugpo.2024.104390
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2024
- Description
- Background: The most recent formulation of buprenorphine treatment is extended-release depot injections (BUP-XR) that are administered subcutaneously by health care professionals. This study aimed to observe treatment outcomes of BUP-XR delivered in standard practice during a 96-week follow-up period in a community setting. Methods: This study is an extension of the CoLAB study, a prospective single-arm, multicentre, open label trial (N=100, 7 sites in Australia) among people with opioid dependence who received monthly injections of BUP-XR to evaluate the retention in treatment. Participants were followed for 96 weeks, comprising 48 weeks of the CoLAB study followed by a 48-week extension. Results: Of 100 participants at baseline, 47 were retained on BUP-XR at 96 weeks. The median time retained on monthly depot was 90 weeks. Heroin use (adjusted OR=0.19, P=0.012) in the month prior to baseline was associated with lower odds of retention on BUP-XR. Older age at first opioid use (adjusted OR= 1.08, P=0.009) and longer duration in OAT at baseline (adjusted OR= 1.12, P=0.001) were associated with increased retention. Prevalence of past four-weeks opioid use was estimated at 4% at 96 weeks of treatment (prevalence 0.04, 95%CI: 0.00-0.11) compared to 15% at baseline. Quality of life and medication treatment satisfaction improved over time for those retained in treatment. Conclusion: This is one of the few studies to describe long term (96 week) retention in treatment with BUP-XR in a community setting. It displayed retention rates with 47% of participants completing 96 weeks of treatment with BUP-XR. Patient reported outcomes suggest improvements in client wellbeing. Funding: Indivior
- Subject
- opioid dependence treatment; retention; extended-release buprenorphine; opioid dependence
- Identifier
- http://hdl.handle.net/1959.13/1501529
- Identifier
- uon:55154
- Identifier
- ISSN:0955-3959
- Language
- eng
- Reviewed
- Hits: 6359
- Visitors: 5515
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|